Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ELAN Stock Summary
Top 10 Correlated ETFs
ELAN
In the News
Elanco Animal Health (ELAN) CEO on Pet Disease Prevention & Health Products
Elanco Animal Health (ELAN) offers pet disease prevention and nutritional health products. CEO Jeffrey Simmons joins Oliver Renick to give an overview of the company.
Here's What Key Metrics Tell Us About Elanco Animal Health Incorporated (ELAN) Q4 Earnings
The headline numbers for Elanco Animal Health Incorporated (ELAN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elanco Animal Health Incorporated (ELAN) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Elanco Animal Health Incorporated (ELAN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elanco Animal Health sells aqua business to Merck for $1.3 billion
Elanco Animal Health Inc has announced the sale of its aqua business to Merck Animal Health for US$1.3 billion in a bid to refocus on other markets. This will enable Elanco to accelerate debt paydown by US$1.05 billion to US$1.1 billion, the company said on Monday, with the proceeds representing over seven times the estimated 2023 revenue of the hot and cold water species product firm.
Elanco Animal Health agrees to sell aqua business to Merck for $1.3 billion in cash
Elanco Animal Health Inc. ELAN, -0.41% said Monday it has agreed to sell its aqua business to Merck Animal Health MRK, +0.02% for $1.3 billion in cash. Greenfield, Ind.
Strength Seen in Elanco Animal Health Incorporated (ELAN): Can Its 6.2% Jump Turn into More Strength?
Elanco Animal Health Incorporated (ELAN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Stifel: ‘party is just getting started' in this stock up 80%
Elanco Animal Health Inc (NYSE: ELAN) has already gained a whopping 80% over the past two months but a Stifel analyst is convinced that the “party is just getting started”.
Elanco Animal Health Incorporated (ELAN) Hit a 52 Week High, Can the Run Continue?
Elanco Animal Health Incorporated (ELAN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ancora picks up a stake in Elanco. How the investor may push to help improve margins
A refreshment of the board may be on the horizon at the animal health company.
ELAN Financial details
ELAN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 8.32 | 7.42 | 9.78 | 9.06 | 8.97 | |
Net income per share | 0.18 | -1.27 | -0.97 | -0.15 | -2.5 | |
Operating cash flow per share | 0.61 | -0.09 | 0.99 | 0.93 | 0.55 | |
Free cash flow per share | 0.07 | -0.8 | 0.59 | 0.55 | 0.24 | |
Cash per share | 0.91 | 1.12 | 1.31 | 0.74 | 0.72 | |
Book value per share | 15.03 | 19.2 | 15.47 | 14.95 | 12.64 | |
Tangible book value per share | 0.2 | -9.37 | -8.66 | -7.27 | -6.84 | |
Share holders equity per share | 15.03 | 19.2 | 15.47 | 14.95 | 12.64 | |
Interest debt per share | 6.6 | 14.22 | 13.45 | 12.47 | 12.29 | |
Market cap | 10.87B | 13.54B | 13.83B | 5.96B | 7.34B | |
Enterprise value | 12.89B | 19.17B | 19.51B | 11.45B | 12.76B | |
P/E ratio | 160.04 | -24.17 | -29.29 | -80.5 | -5.96 | |
Price to sales ratio | 3.54 | 4.14 | 2.9 | 1.35 | 1.66 | |
POCF ratio | 48.49 | -330.19 | 28.63 | 13.18 | 27.07 | |
PFCF ratio | 407.01 | -38.47 | 48.35 | 22.23 | 62.69 | |
P/B Ratio | 1.96 | 1.6 | 1.83 | 0.82 | 1.18 | |
PTB ratio | 1.96 | 1.6 | 1.83 | 0.82 | 1.18 | |
EV to sales | 4.2 | 5.86 | 4.09 | 2.59 | 2.89 | |
Enterprise value over EBITDA | 23.73 | 41.55 | 22.87 | 12.92 | 13.5 | |
EV to operating cash flow | 57.51 | -467.56 | 40.39 | 25.33 | 47.07 | |
EV to free cash flow | 482.7 | -54.48 | 68.21 | 42.72 | 109.04 | |
Earnings yield | 0.01 | -0.04 | -0.03 | -0.01 | -0.17 | |
Free cash flow yield | 0 | -0.03 | 0.02 | 0.04 | 0.02 | |
Debt to equity | 0.42 | 0.72 | 0.84 | 0.8 | 0.93 | |
Debt to assets | 0.26 | 0.35 | 0.38 | 0.38 | 0.4 | |
Net debt to EBITDA | 3.72 | 12.21 | 6.66 | 6.2 | 5.74 | |
Current ratio | 2.9 | 1.65 | 1.99 | 1.93 | 2.75 | |
Interest coverage | 4.34 | 0.68 | 1.26 | 1.49 | 1.18 | |
Income quality | 3.3 | 0.07 | -1.02 | -5.79 | -0.22 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0.24 | 0.24 | 0 | |
Research and developement to revenue | 0.09 | 0.1 | 0.08 | 0.07 | 0.07 | |
Intangibles to total assets | 0.61 | 0.71 | 0.71 | 0.7 | 0.67 | |
Capex to operating cash flow | -0.88 | 7.58 | -0.41 | -0.41 | -0.57 | |
Capex to revenue | -0.06 | -0.09 | -0.04 | -0.04 | -0.03 | |
Capex to depreciation | -0.63 | -0.6 | -0.28 | -0.27 | -0.22 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 7.89 | 23.41 | 18.36 | 7.15 | 26.67 | |
ROIC | 0.04 | 0.01 | 0.02 | 0.03 | 0.03 | |
Return on tangible assets | 0.02 | -0.11 | -0.1 | -0.02 | -0.26 | |
Graham Net | -5.18 | -16.14 | -14.06 | -12.97 | -12.52 | |
Working capital | 1.55B | 1.34B | 1.63B | 1.58B | 2.17B | |
Tangible asset value | 74.5M | -4.14B | -4.22B | -3.55B | -3.37B | |
Net current asset value | -1.07B | -5.8B | -5.67B | -4.92B | -4.73B | |
Invested capital | 0.42 | 0.72 | 0.84 | 0.8 | 0.93 | |
Average receivables | 799.65M | 983.3M | 1.05B | 1.02B | 1.01B | |
Average payables | 213.9M | 361.8M | 459.5M | 404M | 330M | |
Average inventory | 1.03B | 1.31B | 1.48B | 1.46B | 1.64B | |
Days sales outstanding | 105.77 | 120.06 | 78.75 | 82.78 | 83.46 | |
Days payables outstanding | 55.26 | 109.72 | 71.49 | 74.41 | 51.04 | |
Days of inventory on hand | 260.83 | 345.62 | 234.84 | 293.45 | 327.95 | |
Receivables turnover | 3.45 | 3.04 | 4.64 | 4.41 | 4.37 | |
Payables turnover | 6.61 | 3.33 | 5.11 | 4.91 | 7.15 | |
Inventory turnover | 1.4 | 1.06 | 1.55 | 1.24 | 1.11 | |
ROE | 0.01 | -0.07 | -0.06 | -0.01 | -0.2 | |
Capex per share | -0.53 | -0.7 | -0.4 | -0.38 | -0.31 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.02 | 2.56 | 2.18 | 2.17 | 2.1 | |
Net income per share | -0.11 | 0.21 | -0.2 | -2.22 | -0.29 | |
Operating cash flow per share | 0.03 | -0.3 | 0.13 | 0.4 | 0.32 | |
Free cash flow per share | -0.14 | -0.37 | 0.04 | 0.33 | 0.24 | |
Cash per share | 0.73 | 0.66 | 0.84 | 0.75 | 0.71 | |
Book value per share | 14.92 | 15.23 | 15.3 | 12.45 | 12.63 | |
Tangible book value per share | -7.26 | -6.87 | -6.8 | -6.58 | -6.83 | |
Share holders equity per share | 14.92 | 15.23 | 15.3 | 12.45 | 12.63 | |
Interest debt per share | 12.07 | 12.39 | 12.65 | 12.14 | 11.85 | |
Market cap | 5.97B | 4.62B | 4.88B | 5.54B | 7.34B | |
Enterprise value | 11.46B | 10.32B | 10.57B | 11.08B | 12.76B | |
P/E ratio | -27.64 | 11.2 | -12.58 | -1.26 | -13.02 | |
Price to sales ratio | 6.04 | 3.67 | 4.62 | 5.19 | 7.09 | |
POCF ratio | 459.19 | -31.84 | 79.99 | 27.97 | 46.77 | |
PFCF ratio | -90.45 | -25.23 | 256.79 | 33.56 | 63.3 | |
P/B Ratio | 0.82 | 0.62 | 0.66 | 0.9 | 1.18 | |
PTB ratio | 0.82 | 0.62 | 0.66 | 0.9 | 1.18 | |
EV to sales | 11.6 | 8.21 | 10 | 10.37 | 12.33 | |
Enterprise value over EBITDA | 84.27 | 29.82 | 63.7 | 64.03 | 86.83 | |
EV to operating cash flow | 881.57 | -71.16 | 173.35 | 55.95 | 81.3 | |
EV to free cash flow | -173.64 | -56.38 | 556.53 | 67.14 | 110.04 | |
Earnings yield | -0.01 | 0.02 | -0.02 | -0.2 | -0.02 | |
Free cash flow yield | -0.01 | -0.04 | 0 | 0.03 | 0.02 | |
Debt to equity | 0.8 | 0.8 | 0.82 | 0.96 | 0.93 | |
Debt to assets | 0.38 | 0.38 | 0.38 | 0.41 | 0.4 | |
Net debt to EBITDA | 40.38 | 16.48 | 34.31 | 32.02 | 36.88 | |
Current ratio | 1.93 | 2.25 | 2.84 | 2.82 | 2.75 | |
Interest coverage | 0.1 | 3.31 | 0.72 | 0.58 | -0.36 | |
Income quality | -0.24 | -1.41 | -0.63 | -0.18 | -1.11 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.1 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.08 | 0.06 | 0.08 | 0.08 | 0.08 | |
Intangibles to total assets | 0.7 | 0.69 | 0.68 | 0.65 | 0.67 | |
Capex to operating cash flow | -6.08 | 0.26 | -0.69 | -0.17 | -0.26 | |
Capex to revenue | -0.08 | -0.03 | -0.04 | -0.03 | -0.04 | |
Capex to depreciation | -0.47 | -0.22 | -0.24 | -0.19 | -0.24 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 6.09 | 8.48 | 8.3 | 24.96 | 9.02 | |
ROIC | 0 | 0.01 | 0 | 0 | 0 | |
Return on tangible assets | -0.01 | 0.02 | -0.02 | -0.22 | -0.03 | |
Graham Net | -12.94 | -12.66 | -12.79 | -12.47 | -12.5 | |
Working capital | 1.58B | 1.97B | 2.37B | 2.3B | 2.17B | |
Tangible asset value | -3.55B | -3.37B | -3.3B | -3.24B | -3.37B | |
Net current asset value | -4.92B | -4.74B | -4.72B | -4.65B | -4.73B | |
Invested capital | 0.8 | 0.8 | 0.82 | 0.96 | 0.93 | |
Average receivables | 1.02B | 1.13B | 1.24B | 1.18B | 1.07B | |
Average payables | 370M | 385.5M | 367.5M | 325M | 283M | |
Average inventory | 1.44B | 1.57B | 1.64B | 1.69B | 1.71B | |
Days sales outstanding | 91.28 | 90.5 | 104.3 | 95.65 | 87.83 | |
Days payables outstanding | 78.35 | 69.41 | 73.41 | 54.7 | 47.09 | |
Days of inventory on hand | 308.97 | 290.77 | 350.46 | 312.32 | 302.62 | |
Receivables turnover | 0.99 | 0.99 | 0.86 | 0.94 | 1.02 | |
Payables turnover | 1.15 | 1.3 | 1.23 | 1.65 | 1.91 | |
Inventory turnover | 0.29 | 0.31 | 0.26 | 0.29 | 0.3 | |
ROE | -0.01 | 0.01 | -0.01 | -0.18 | -0.02 | |
Capex per share | -0.16 | -0.08 | -0.09 | -0.07 | -0.08 |
ELAN Frequently Asked Questions
What is Elanco Animal Health Incorporated stock symbol ?
Elanco Animal Health Incorporated is a US stock , located in Greenfield of In and trading under the symbol ELAN
Is Elanco Animal Health Incorporated buy or a sell ?
8 stock analysts have 8 predictions with a medium analyst target price of $25. The lowest prediction is $18 and the highest is $37
What is ELAN stock prediction ?
With a median analyst target price of $19, 2 stock analysts have made 2 forecasts in last 90 days. $18 is the lowest and $20 is the greatest projection.
What is Elanco Animal Health Incorporated stock quote today ?
Elanco Animal Health Incorporated stock price is $16.295 today.
Is Elanco Animal Health Incorporated stock public?
Yes, Elanco Animal Health Incorporated is a publicly traded company.